Foff Erin Pennock 4

What Happened
Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics (MPLT), sold a total of 47,158 shares in a series of open-market transactions between July 15 and July 17, 2026, yielding approximately $1,734,490 in proceeds. Individual transactions reported include: 7,155 shares at $36.16 ($258,725), 7,845 shares at $37.04 ($290,579), 4,465 shares at $36.00 ($160,740), 8,972 shares at $36.99 ($331,874), an 18-share sale at $37.54 ($676), 9,163 shares at $36.46 ($334,083), 5,865 shares at $37.26 ($218,530), a 19-share sale at $37.96 ($721), and 3,656 shares at $37.90 ($138,562). All transactions are coded as sales (S).

Key Details

• Transaction dates: July 15–17, 2026; filing date: July 17, 2026 (Form 4 filed same day).
• Aggregate sold: 47,158 shares for ~$1,734,490.
• Shares owned after transaction: Not specified in the provided filing data.
• Notable footnotes: the filing states the trades were made pursuant to a Rule 10b5-1 trading plan adopted Dec 29, 2025; one small sale was a mandatory "sell to cover" to satisfy statutory tax withholding on vested RSUs; several prices are reported as weighted averages covering ranges of per‑share prices (full breakdown available from the issuer/SEC on request).
• Transaction type code: S = Sale; F4 corresponds to tax-withholding (sell-to-cover) treatment in the footnotes.

Context
Sales by executives can be routine (planned trading under 10b5-1 plans or to cover taxes) and do not necessarily signal a change in company outlook. The presence of a 10b5-1 plan indicates many of these sales were pre-arranged, and the "sell to cover" sale reflects a non‑discretionary tax withholding event. Retail investors should treat purchases as stronger indicators of insider confidence than routine, pre-planned sales.